Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,094 public trials 2,044 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

NCT00532675

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSF Medical Center San Francisco, California, United States
  • Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst. Atlanta, Georgia, United States
  • St. Vincent's Comprehensive Cancer Center New York, United States
  • Novartis Investigative Site South Brisbane, Queensland, Australia
View Trial Details
Completed

Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma

NCT01854606

Conditions
CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Washington University School of Medicine Dept of Oncology. St Louis, Missouri, United States
  • Memorial Sloan Kettering Cancer Center Onc. Dept. New York, United States
  • Sarah Cannon Research Institute Dept of Onc Nashville, Tennessee, United States
  • Novartis Investigative Site Rouen, France
View all 15 locations
View Trial Details
Completed

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

NCT01058434

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst. Mobile, Alabama, United States
  • Central Hematology Oncology Medical Group Alhambra, California, United States
  • Central Coast Medical Oncology Corporation Santa Maria, California, United States
  • St. Jude Heritage Medical Group Virginia Crosson Cancer Center Yorba Linda, California, United States
View all 30 locations
View Trial Details
Completed

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

NCT00532389

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch Miami Shores, Florida, United States
  • Dana Farber Cancer Institute Clinical Research Coordinator Boston, Massachusetts, United States
  • Hackensack University Medical Center Multiple Myeloma Division Hackensack, New Jersey, United States
  • Swedish Medical Center Dept.ofSwedishMedicalCtr. Seattle, Washington, United States
View all 16 locations
View Trial Details
Completed

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

NCT00670592

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin's Lymphoma, +9 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • St. Francis Cancer Research Foundation Dept.ofSt.FrancisCancerRes.(2) Beech Grove, Indiana, United States
  • Dana Farber Cancer Institute SC-5 Boston, Massachusetts, United States
  • Wake Forest University Baptist Medical Center Dept. of Industry Research (2) Winston-Salem, North Carolina, United States
View all 28 locations
View Trial Details
Completed

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

NCT02144038

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(SC) Houston, Texas, United States
  • Seattle Cancer Care Alliance Oncology Dept Seattle, Washington, United States
  • University of Wisconsin / Paul P. Carbone Comp Cancer Center Dept of Onc. Madison, Wisconsin, United States
  • Novartis Investigative Site Prahran, Victoria, Australia
View Trial Details
Completed

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.

NCT01237236

Conditions
Advanced Solid Tumor, Hemic and Lymphatic Diseases, Immune System Diseases, +7 more
Locations
  • Dana Farber Cancer Institute DFCI Boston, Massachusetts, United States
  • University of Michigan Comprehensive Cancer Center SC Ann Arbor, Michigan, United States
  • Memorial Sloan Kettering MSKCC (2) New York, United States
  • Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2) Nashville, Tennessee, United States
View Trial Details
Completed

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

NCT01337752

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Female Urogenital Diseases, +19 more
Locations
  • University Chicago Hospital Dept. of Univ of Chicago (2) Chicago, Illinois, United States
  • Medical Oncology Associates, PS Spokane, Washington, United States
  • Novartis Investigative Site Valencia, Spain
  • Novartis Investigative Site Madrid, Spain
View Trial Details
Completed

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

NCT00708292

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Mayo Clinic - Arizona Cancer Clinical Research Unit Scottsdale, Arizona, United States
  • Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3) San Antonio, Texas, United States
  • Novartis Investigative Site Melbourne, Australia
  • Novartis Investigative Site Frankfurt, Germany
View Trial Details

Related conditions